ImetelChat

A recent video with Dr. Mascarenhas. https://www.onclive.com/view/dr-mascarenhas-on-the-promise-of-imetelstat-in-myelofibrosis REMINDER: The IMbark trial yielded a survival benefit despite having a number of patients drop out early based on lack of spleen response. Our upcoming Phase 3 trial (Impact...

Someone should let JSAN (Jeremy Smith) know the world's leading hematologists are taking an active interest (role) in our upcoming MF Phase 3 clinical trial. That was always his main contention with Imetelstat (i.e. lack of KOL support and/or participation). http://www.mpnresearchfoundation.org/Jere...

Notably Present: Mascarenhas, Harrison, and Verstovsek. VERY Notably Present: Mesa & Vannucchi** **Dr. Vannucchi Disclosure.....AbbVie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene/BMS: Membership on an entity's Board of Directors or advisory committe...

The most obvious answer(s) in my opinion.....

1) Use the proceeds to launch an AML clinical trial.
2) Extra funds to support MF and/or MDS trials (more sites, extended time, etc)
3) Acquire a promising new compound. I think they would pursue #1 before #3, but ???

BP, The 6-thio-G compound is shown in the specification (p. 67) of two Geron patents (US9593137B2, US10035814B2), but the compound is NOT specifically mentioned in the patent claims. Thus, I conclude Geron does NOT have broad protections involving the 6-thio compound(s). However, as mentioned in my ...

I’m hoping one or both of our new investors with over 10 percent ownership will be able to get seats on the BOD. I think it would be good to have someone on the board who represents a meaningful financial stake in the company.

Recent presentations have made it clear the FDA will not consider Real World Data (RWD) in support of a drug's initial approval. This explains why we weren't allowed A) an early approval based on our P2 IMbark results, or B) an open-label P3 Registration trial using RWD as a synthetic control arm (a...

If we demonstrate a survival benefit and/or fibrosis improvement in our P3 Registration trial, we could realize significant off-label sales as a frontline MF treatment (following our R/R MF approval). Thus, we may be more of a threat to Jakafi sales than one would think....based solely on our curren...